Good News | magAssist Nominated Again for the 2026 Prix Galien USA Best Startup Award

Recently, The Galien Foundation announced the nominees for the 2026 Prix Galien USA Awards. As Prix Galien USA marks its 20th anniversary, magAssist has once again been nominated for the Best Startup award.

This marks the second consecutive year that magAssist has been nominated in the Best Startup category at the Prix Galien USA. The nomination reflects continued international interest in magAssist's work in artificial heart and life-support technologies, as well as its ongoing R&D efforts and development potential.

——2026 Prix Galien USA Nomination——

An International Award Recognizing Innovation in Life Sciences

Established in 1970 and named after Galen, a physician whose work influenced the development of modern medicine, the Prix Galien has focused on recognizing innovation in the life sciences for more than five decades and is regarded as an important international award in the field.

Since its establishment in 2007, Prix Galien USA has recognized innovative technologies and solutions in healthcare. Its international expert panel evaluates nominees based on factors including scientific innovation, clinical value, and potential benefits to patients, with the aim of recognizing innovations that contribute to advances in healthcare and patient outcomes.

In 2026, Prix Galien USA marks its 20th anniversary. The Galien Foundation has selected "Celebrating 20 Years of Honoring the Digital Breakthroughs, Pioneering Startups, and Ecosystems Driving the Future of Healthcare" as the theme for the anniversary year.

Photo taken at the 2025 Prix Galien Awards

——2026 Prix Galien USA Nomination——

Recognizing Continued Innovation

magAssist has been nominated for the Prix Galien USA Best Startup category for the second consecutive year. The consecutive nominations recognize the company's continued focus on research and development in Mechanical Circulatory Support (MCS).

2026 Prix Galien USA Best Startup nominees (magAssist Co., Ltd. highlighted)

Since its establishment, magAssist has focused on significant unmet clinical needs and sought to advance next-generation artificial heart and life-support technologies through the integration of medical and engineering expertise.

The company has developed a product portfolio covering cardiac support and multi-organ support applications, including:

• NyokAssist®: A 9Fr collapsible percutaneous ventricular assist device designed for short-term circulatory support during high-risk PCI. It has received Breakthrough Device Designation from the U.S. FDA.

• MoyoAssist®: A fully magnetically levitated extracorporeal ventricular assist device designed to provide short- to intermediate-term circulatory support. It has been approved by the National Medical Products Administration (NMPA) for circulatory support in patients with cardiogenic shock.

• BreathMo® ECMO: An ECMO system based on a unified fully magnetically levitated pump platform, designed to provide combined cardiopulmonary support.

Exploring the Future of Life-Support Technologies

Being nominated again for the Prix Galien USA Best Startup award reflects magAssist's continued efforts to develop life-support technologies and engage with the international medical innovation community. It also provides an opportunity to highlight innovation from a Chinese medical device company in the field of life support.

Looking ahead, magAssist will continue to focus on clinical needs and advance the development and application of artificial heart and life-support technologies. The company will work with clinical experts, research institutions, and industry partners around the world to explore new approaches to life support and develop solutions for critically ill patients.

Disclaimer: MoyoAssist® has been approved by the National Medical Products Administration (NMPA) for circulatory support in patients with cardiogenic shock. NyokAssist® and BreathMo® are currently intended for research and academic exchange only. They have not been approved by the National Medical Products Administration (NMPA) and are not commercially available in any country or region. Nothing in this article constitutes advertising, an offer for sale, or medical advice.